Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.…
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
Invivyd (NASDAQ: IVVD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 122 employees.
The shares were at 0.4127 USD on 20 November 2026, down 74.0% over 52 weeks. Its 52-week range is 0.4127 USD to 3.070 USD, and it trades at the bottom of that range.
Its market capitalisation is 122.01M USD.
Invivyd reports return on equity of -21.7%, an operating margin of -224.4% and revenue up 17.7% year over year.
It holds more cash than debt, a net cash position of 118.15M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 4 March 2027.